The lancet oncology
-
The lancet oncology · Oct 2017
Randomized Controlled Trial Multicenter Study Comparative StudyCarfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups. ⋯ Onyx Pharmaceuticals Inc, an Amgen Inc subsidiary.
-
The lancet oncology · Oct 2017
Randomized Controlled Trial Multicenter Study Comparative StudyGemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma. ⋯ Cancer Research UK, Sarcoma UK, and Clinical Trial Unit Kantonsspital St Gallen.